NCT02995993 - Pharmacokinetics, Pharmacodynamics, and Safety of Moss-aGalactosidase A in Patients With Fabry Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

October 9, 2017

Study Completion Date

October 9, 2017

Conditions

Fabry Disease

Interventions

DRUG

Moss-aGal (recombinant human alpha-galactosidase A produced in moss)

Single i.v. Infusion of 0.2 mg/kg moss-aGal over 60 minutes

Trial Locations (2)

Ruhruniversität Bochum, Klinik für Kinder- und Jugendmedizin im St. Josef-Hospital im Katholischen Klinikum Bochum, Bochum

Universitätsmedizin Mainz, Zentrum für Kinder- und Jugendmedizin, Mainz